Hepatitis A vaccine immune response 22 years after vaccination.

Mosites, Emily; Gounder, Prabhu; Snowball, Mary; Morris, Julie; Spradling, Philip; Nelson, Noele; Bulkow, Lisa; Bruce, Michael; McMahon, Brian

doi:10.1002/jmv.25197

Cited by 25Hepatitis Viruses Studies and EpidemiologyHepatitis B Virus StudiesViral gastroenteritis research and epidemiology

Hepatitis A vaccine immune response 22 years after vaccination.

Mosites, Emily, Gounder, Prabhu, Snowball, Mary, Morris, Julie, Spradling, Philip, Nelson, Noele, Bulkow, Lisa, Bruce, Michael +1 more·2018·Journal of Medical Virology

DOI 10.1002/jmv.25197

Open this paper in CoChat — free account

Abstract

In the United States, the incidence of hepatitis A virus (HAV) infection has been reduced through universal childhood vaccination. However, the duration of immunogenicity for the hepatitis A vaccine is not known. We report on the 22 year follow-up time point of a cohort of Alaska children who were randomized to three different vaccine schedules: A) 0, 1, and 2 months; B) 0, 1, and 6 months; and C) 0, 1, and 12 months. Among 46 participant available for follow-up, 40 (87%) maintained protective levels of anti-hepatitis A antibody. These results indicate that a supplemental booster dose is not yet necessary at or before the 22-year time point.

Integrity signals

Registry

Crossref · 10.1002/jmv.25197

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

A study of Alaska Natives demonstrated that seropositivity for hepatitis A persists for >20 years after completing 2-dose vaccination at age 12-21 months.
“A study of Alaska Natives demonstrated that seropositivity for hepatitis A persists for >20 years after completing 2-dose vaccination at age 12–21 months (1302).”
From Sexually Transmitted Infections Treatment Guidelines, 2021 (2021) · cites this paper as [1302]
Kinetic models of antibody decrease among adults indicate that protective levels persist for >40 years.
“Kinetic models of antibody decrease among adults indicate that protective levels persist for >40 years (1302–1304).”
From Sexually Transmitted Infections Treatment Guidelines, 2021 (2021) · cites this paper as [1302]

World Health Organization Global Estimates and Regional Comparisons of the Burden of Foodborne Disease in 2010
Havelaar, A. H., Kirk, M. D., Torgerson, P. R., Gibb, H. J., Hald, T., Lake, R. J., Praet, N., Bellinger, D. C., de Silva, N. R., Gargouri, N., et al. (2015) · PLoS Medicine · doi:10.1371/journal.pmed.1001923 · Cited by 2,067 · see citing works
4. Regression with Missing Ys: An Improved Strategy for Analyzing Multiply Imputed Data
von Hippel, P. T. (2007) · Sociological Methodology · doi:10.1111/j.1467-9531.2007.00180.x · Cited by 1,495 · see citing works
Prevention of Hepatitis A Through Active or Passive Immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
Fiore, A. E., Wasley, A., & Bell, B. P. (1999) · PsycEXTRA Dataset · doi:10.1037/e547812006-001 · Cited by 1,130 · see citing works
Prevention of Hepatitis A Through Active or Passive Immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
(1996) · PsycEXTRA Dataset · doi:10.1037/e547222006-001 · Cited by 431 · see citing works
Clinical manifestations and diagnosis of hepatitis A virus infection
Koff, R. S. (1992) · Vaccine · doi:10.1016/0264-410x(92)90533-p · Cited by 188 · see citing works
Trends in Disease and Complications of Hepatitis A Virus Infection in the United States, 1999–2011: A New Concern for Adults
Ly, K. N., & Klevens, R. M. (2015) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu834 · Cited by 101 · see citing works
Long-term protective effects of hepatitis A vaccines. A systematic review
Ott, J. J., Irving, G. J., & Wiersma, S. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.04.104 · Cited by 95 · see citing works
Immunogenicity Of An Inactivated Hepatitis A Vaccine In Alaska Native Children And Native And Non-Native Adults
McMahon, B. J., Williams, J. L., BULKOW, L. R., Snowball, M. M., Wainwright, R. B., Kennedy, M., & Krause, D. (1995) · The Journal of Infectious Diseases · doi:10.1093/infdis/171.3.676 · Cited by 94 · see citing works
Long-term antibody persistence after vaccination with a 2-dose Havrix™ (inactivated hepatitis A vaccine): 20 years of observed data, and long-term model-based predictions
Theeten, H., Van Herck, K., Van Der Meeren, O., Crasta, P., Van Damme, P., & Hens, N. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.07.008 · Cited by 82 · see citing works
Progress Toward Eliminating Hepatitis A Disease in the United States
Murphy, T. V., Denniston, M. M., Hill, H. A., McDonald, M., Klevens, M. R., Elam–Evans, L. D., Nelson, N. P., Iskander, J. K., & Ward, J. D. (2016) · MMWR Supplements · doi:10.15585/mmwr.su6501a6 · Cited by 77 · see citing works
Immunogenicity of an Inactivated Hepatitis A Vaccine in Infants and Young Children
Bell, B. P., Negus, S. E., Fiore, A. E., Plotnik, J. N., Dhotre, K. B., Williams, J. L., Shapiro, C. N., & McMahon, B. J. (2007) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000253253.85640.cc · Cited by 68 · see citing works
Persistence of Antibody to Hepatitis A Virus 10 Years after Vaccination among Children and Adults
Hammitt, L. L., BULKOW, L. R., Hennessy, T. W., Zanis, C. L., Snowball, M. M., Williams, J. L., Bell, B. P., & McMahon, B. J. (2008) · The Journal of Infectious Diseases · doi:10.1086/593335 · Cited by 64 · see citing works
Secular Trends in Hepatitis A Virus Infection among Alaska Natives
BULKOW, L. R., Wainwright, R. B., McMahon, B. J., Middaugh, J. P., Jenkerson, S. A., & Margolis, H. S. (1993) · The Journal of Infectious Diseases · doi:10.1093/infdis/168.4.1017 · Cited by 46 · see citing works
Long-Term Immunogenicity of Hepatitis A Virus Vaccine in Alaska 17 Years After Initial Childhood Series
Raczniak, G. A., BULKOW, L. R., Bruce, M. G., Zanis, C. L., Baum, R. L., Snowball, M. M., Byrd, K. K., Sharapov, U. M., Hennessy, T. W., & McMahon, B. J. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis710 · Cited by 32 · see citing works
Duration of protection against hepatitis A for the current two-dose vaccine compared to a three-dose vaccine schedule in children
Raczniak, G. A., Thomas, T. K., BULKOW, L. R., Negus, S. E., Zanis, C. L., Bruce, M. G., Spradling, P. R., Teshale, E. H., & McMahon, B. J. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.02.048 · Cited by 30 · see citing works
Viral hepatitis in the Arctic
McMahon, B. J. (2004) · International Journal of Circumpolar Health · doi:10.3402/ijch.v63i0.17784 · Cited by 30 · see citing works
Impact of a statewide childhood vaccine program in controlling hepatitis A virus infections in Alaska
Singleton, R. J., Hess, S., BULKOW, L. R., Castrodale, L. J., Provo, G., & McMahon, B. J. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.06.113 · Cited by 28 · see citing works
Impact of Recurrent Epidemics of Hepatitis A Virus Infection on Population Immunity Levels: Bristol Bay, Alaska
Peach, D., McMahon, B. J., BULKOW, L. R., Funk, E. A., Harpaz, R., & Margolis, H. S. (2002) · The Journal of Infectious Diseases · doi:10.1086/343815 · Cited by 22 · see citing works
Persistence of antibody to Hepatitis A virus 20 years after receipt of Hepatitis A vaccine in Alaska
Plumb, I. D., BULKOW, L. R., Bruce, M. G., Hennessy, T. W., Morris, J. M., Rudolph, K. M., Spradling, P. R., Snowball, M. M., & McMahon, B. J. (2017) · Journal of Viral Hepatitis · doi:10.1111/jvh.12676 · Cited by 20 · see citing works
Risk factors for hospitalisation and associated costs among patients with hepatitis A associated with imported pomegranate arils, United States, 2013
Epson, E. E., Cronquist, A., Lamba, K., Kimura, A. C., Hassan, R., Selvage, D., McNeil, C. S., Varan, A. K., Silvaggio, J., Fan, L., et al. (2016) · Public Health · doi:10.1016/j.puhe.2016.03.027 · Cited by 9 · see citing works

Flagged first, then by citations

1 of the 21 references couldn’t be matched to a known paper.

Sorted by citations

Sexually Transmitted Infections Treatment Guidelines, 2021
Workowski, K. A., Bachmann, L. H., Chan, P. A., Johnston, C. M., Muzny, C. A., Park, I., Reno, H., Zenilman, J. M., & Bolan, G. A. (2021) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr7004a1 · Cited by 2,759 · see citing works
Prevention of Hepatitis A Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2020
Nelson, N. P., Weng, M. K., Hofmeister, M. G., Moore, K. L., Doshani, M., Kamili, S., Koneru, A., Haber, P., Hagan, L., Romero, J. R., et al. (2020) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr6905a1 · Cited by 264 · see citing works
Hepatitis A vaccination and its immunological and epidemiological long-term effects – a review of the evidence
Herzog, C., Herck, K. V., & Damme, P. V. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1819742 · Cited by 77 · see citing works
Changing Epidemiology of Hepatitis A in China: Evidence From Three National Serological Surveys and the National Notifiable Disease Reporting System
Wang, F., Sun, X., Wang, F., Zheng, H., Jia, Z., Zhang, G., Bi, S., Miao, N., Zhang, S., Cui, F., et al. (2020) · Hepatology · doi:10.1002/hep.31429 · Cited by 35 · see citing works
“(26) A follow-up study in the United States showed that 87% of vaccinated individuals maintained protective levels of anti-HAV in 22-years time after initial vaccination, leading to a conclusion that a booster dose was not yet necessary 22 years after vaccination with inactivated HepA.”
BackgroundInfluential
One or two doses of hepatitis A vaccine in universal vaccination programs in children in 2020: A systematic review
Andani, A., Damme, P. V., Bunge, E. M., Salgado, F. D. A., van Hoorn, R. C., & Hoet, B. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.01.038 · Cited by 35 · see citing works
The History of Hepatitis A
Shouval, D. (2020) · Clinical Liver Disease · doi:10.1002/cld.1018 · Cited by 21 · see citing works
Hepatitis A vaccine immunogenicity 25 years after vaccination in Alaska
Ramaswamy, M., Bruden, D. J. T., Nolen, L. D., Mosites, E. M., Snowball, M. M., Nelson, N. P., Bruce, M. G., & McMahon, B. J. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26327 · Cited by 13 · see citing works
“Laboratory methods for assessing anti‐HAV concentrations have been described elsewhere.(12) We assessed IgG anti‐HAV concentrations at each time point by calculating the geometric mean concentration (GMC) and calculated the proportion of participants with protective levels of anti‐HAV (≥20mIU/mL) at each time point.”
Method
Serologic evidence of the circulation of the hepatitis E virus and the prevalence of antibodies against hepatitis A in an indigenous population in northern Argentina
Remondegui, C., Ceballos, S., Arce, L. P., Pintado, E., Vidaurre, R., Nitschko, H., Osterman, A., & Vizoso-Pinto, M. G. (2021) · Revista Argentina de Microbiología · doi:10.1016/j.ram.2020.10.006 · Cited by 11 · see citing works
Hepatitis A in Latin America: The current scenario
Re, V. E., Ridruejo, E., Fantilli, A. C., Moutinho, B., Pisano, M. B., & Pessôa, M. G. (2024) · Reviews in Medical Virology · doi:10.1002/rmv.2566 · Cited by 9 · see citing works
Low Prevalence of Vaccination or Documented Immunity to Hepatitis A and Hepatitis B Viruses Among Individuals with Chronic Liver Disease
Wong, R. J., Gish, R. G., Cheung, R. C., & Chitnis, A. S. (2021) · The American Journal of Medicine · doi:10.1016/j.amjmed.2021.02.008 · Cited by 6 · see citing works
Viral Hepatitis
Neuhoff, B. K. (2025) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000938 · Cited by 5 · see citing works
Immunogenicity of Viral Vaccines in the Italian Military
Ferlito, C., Biselli, R., Visco, V., Cattaruzza, M. S., Capobianchi, M. R., Castilletti, C., Lapa, D., Nicoletti, L., Marchi, A., Magurano, F., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9010087 · Cited by 5 · see citing works
Hepatitis A
Foster, M. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819519-2.00023-2 · Cited by 4 · see citing works
Vaccination Status of Alaska Native Persons With Hepatitis A Virus Infection—Alaska, 1996–2018
Plumb, I. D., Gounder, P. P., Nolen, L. D., Massay, S., Castrodale, L. J., McLaughlin, J. B., Snowball, M. M., Homan, C., Nelson, N. P., Singleton, R. J., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1102 · Cited by 3 · see citing works
“Initial trials demonstrated vaccine efficacy of 94%–100% against clinical infection [1], and follow-up studies indicate the persistence of protective levels of antibody for at least 20 years [9].”
Background
Immunogenicity, long term protection and safety of subcutaneous administration of hepatitis A vaccine in patients with hemophilia and other bleeding disorders: A randomized study
Nakasone, M., Lopes, M. H., Sartori, A. M. C., Sandoval, E. P. N., Villaça, P. R., D’Amico, É. A., & Carneiro, J. D. A. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.04.040 · Cited by 3 · see citing works
Vaccination Strategies Against Hepatic Diseases: A Scoping Review
Beyzaei, Z., Geramizadeh, B., Karimzadeh, S., & Weiskirchen, R. (2025) · Vaccines · doi:10.3390/vaccines14010049 · Cited by 2 · see citing works
“Ramaswamy et al., [17], Mosites et al., [23], and Spradling et al., [33] reported that protective anti-HAV antibody levels remained for 10–25 years, with models predicting persistence for ≥ 30 years in most participants.”
Effectiveness of hepatitis A immunization after pediatric liver transplantation: A retrospective observational analysis
Laue, T., Junge, N., Leiskau, C., Mutschler, F. E., Ohlendorf, J., & Baumann, U. (2024) · American Journal of Transplantation · doi:10.1016/j.ajt.2024.12.009 · Cited by 2 · see citing works
Long‐term persistence of anti‐HAV antibody conferred by a single dose of live‐attenuated hepatitis A vaccine: Results from 17‐year follow‐up
Chen, Y., Zhao, Y., Hao, Z.-Y., Zhang, X., Ma, J., Zhang, Z., Zhang, Y., Zhao, G., Qiu, C., Kilgore, P. E., et al. (2021) · Journal of Viral Hepatitis · doi:10.1111/jvh.13602 · Cited by 2 · see citing works
Modeling the Long-term Antibody Response and Duration of Immune Protection Induced by an Inactivated, Preservative-free Hepatitis A Vaccine (Healive) in Children.
Yu, Y. P., Chen, J. T., Jiang, Z. W., Wang, L., Yu, C. K., Yan, X., Yao, C., & Xia, J. L. (2020) · PubMed · doi:10.3967/bes2020.065 · Cited by 1 · see citing works
Caracterização molecular das cepas do vírus da hepatite A envolvidas no surto identificado na cidade de São Paulo no período de 2017 a 2019
Chuffi, S. (2021) · doi:10.11606/d.5.2021.tde-05042022-120710
Avaliação da resposta imune de crianças acompanhadas no estudo MINA às vacinas de sarampo, caxumba e hepatite A
Ferreira, M. S. (2022) · doi:10.11606/d.5.2022.tde-03102022-112758
Hepatitis A Virus
Weng, M. K., Nelson, N. P., & Foster, M. A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-75608-2.00237-8
Pre-COVID19 pandemia vaccines could have a nonspecific effect in preventing SARS-CoV-2 infection in the pediatric population
Dima, V., Iancu, G., Bohîlțea, R. E., Stanescu, R. M., Toma, A. I., Varlas, V. N., & Daviţoiu, A. M. (2022) · Romanian Journal of Pharmaceutical Practice · doi:10.37897/rjphp.2022.2.1
Koronavirüs-19 Enfeksiyonu Olan ve Olmayan Olguların Hepatit A Virüsüne Karşı Kazanılmış İmmün Yanıt Açısından Karşılaştırılması: Retrospektif Bir Çalışma
Bal, T., Yaqoobi, H., Önlen, Y., Çabalak, M., & Doğan, S. (2023) · Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi · doi:10.17517/ksutfd.1102741
Association between hepatitis A B vaccination and hearing loss across frequencies based on NHANES
Qie, R.-J., Qin, J.-B., & Ji, Z. (2025) · Scientific Reports · doi:10.1038/s41598-025-07168-2

Persistence of antibody to Hepatitis A virus 20 years after receipt of Hepatitis A vaccine in Alaska
Plumb, I. D., BULKOW, L. R., Bruce, M. G., Hennessy, T. W., Morris, J. M., Rudolph, K. M., Spradling, P. R., Snowball, M. M., & McMahon, B. J. (2017) · Journal of Viral Hepatitis · doi:10.1111/jvh.12676 · Cited by 20 · see citing works
Hepatitis A vaccine immunogenicity 25 years after vaccination in Alaska
Ramaswamy, M., Bruden, D. J. T., Nolen, L. D., Mosites, E. M., Snowball, M. M., Nelson, N. P., Bruce, M. G., & McMahon, B. J. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26327 · Cited by 13 · see citing works
Immunogenicity of the hepatitis A vaccine 20 years after infant immunization.
Mosites, E., Seeman, S., Negus, S., Homan, C., Morris, J., Nelson, N. P., Spradling, P. R., Bruce, M., & McMahon, B. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.05.069 · Cited by 11 · see citing works
Long-Term Immunogenicity of Hepatitis A Virus Vaccine in Alaska 17 Years After Initial Childhood Series
Raczniak, G. A., BULKOW, L. R., Bruce, M. G., Zanis, C. L., Baum, R. L., Snowball, M. M., Byrd, K. K., Sharapov, U. M., Hennessy, T. W., & McMahon, B. J. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis710 · Cited by 32 · see citing works
Long-term follow-up of hepatitis A vaccination in children
Chan, C., Lee, S.-D., Yu, M., Wang, Y., Chang, F.-Y., & Lo, K. (1999) · Vaccine · doi:10.1016/s0264-410x(98)00200-x · Cited by 34 · see citing works

Authors: Mosites, E., Gounder, P., Snowball, M., Morris, J., Spradling, P., Nelson, N., Bulkow, L., Bruce, M., & McMahon, B.
Affiliations: Centers for Disease Control and Prevention (US)
Alaska Native Tribal Health Consortium (US)
Corresponding author: Mosites, Emily
ORCID: Mosites, Emily
Gounder, Prabhu
Spradling, Philip
Nelson, Noele
Bruce, Michael
McMahon, Brian
Venue: Journal of Medical Virology
Publisher: Wiley
Published: 2018-05
Volume: 90
Issue: 8
Pages: 1418-1422
ISSN: 0146-6615 (ISSN-L)
1096-9071
DOI: 10.1002/jmv.25197
OpenAlex: W2796842874
Cited by: 25
References: 21
Citations by year: 2025: 3 · 2024: 2 · 2023: 1 · 2022: 3 · 2021: 8 · 2020: 8
FWCI: 2.51
Type: journal article
Language: en
Open access: closed
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Journal of Medical Virology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Hepatology › Hepatitis Viruses Studies and Epidemiology
Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
Health Sciences › Medicine › Infectious Diseases › Viral gastroenteritis research and epidemiology
Keywords: hepatitis A vaccine, long-term immunogenicity, booster vaccination, childhood immunization schedule, hepatitis A
MeSH terms: Adult, Alaska, Child, Child, Preschool, Female, Follow-Up Studies, Hepatitis A, Humans, Immunization Schedule, Male, Time Factors, Hepatitis A Vaccines, Hepatitis A virus, Hepatitis A Antibodies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Hepatitis A vaccine immune response 22 years after vaccination.

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks